Dr. Rui Wu holds a PhD in biochemistry and possesses extensive experience in biomedicine, neuroscience research, and business development. Dr. Wu was an integral part of Graviton since its inception, collaborating closely with Dr. Waksal from the acquisition of the first and foundational asset through all stages of therapeutic development for use in clinical trials. Prior to her tenure at Graviton, Dr. Wu served as Senior VP of Preclinical Research and CMC Operations at Équilibre Biopharmaceuticals. Here, she guided the program through the preclinical, formulation development, and manufacturing stages. During her doctoral studies, Dr. Wu contributed to the team led by Richard Silverman that developed the second-generation Lyrica, CPP-115, an anti-epilepsy drug later acquired by Pfizer for clinical development. Additionally, she was involved in the exploration of activators targeting β-glucocerebrosidase for the treatment of Gauche disease and Parkinson's disease, which led to the establishment of Vanqua Bio under the guidance of Dimitri Krainc and Peter Lansbury. In her postdoctoral studies, Dr. Wu developed a novel method enabling high-throughput screening of small molecules for non-enzymatic targets. This method was licensed by MeiraGTx, where she previously spearheaded the small-molecule retomer drug discovery division.